National Cancer Institute (NCI): Liver Neoplasms trials

The registry lists 68 Liver Neoplasms studies with National Cancer Institute (NCI) as lead sponsor. 4 are open to participants now and 25 have results posted.

Early Phase 1 1Phase 1 23Phase 2 38No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor MicroenvironmentEnrolling by invitationNCT05600933
• GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor MalignanciesRecruitingNCT05003895Phase 1
• Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer StudiesRecruitingNCT00451022
• Collection of Blood From Patients With CancerRecruitingNCT00034216
• 18F-DCFPyL PET/CT in Hepatocellular CarcinomaTerminatedNCT05009979Phase 2Results posted
• Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic CancersTerminatedNCT03785210Phase 2Results posted
• Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous CancerTerminatedNCT03480152Phase 1/2Results posted
• Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by SurgeryCompletedNCT02042443Phase 2Results posted
• T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing CancerCompletedNCT01967823Phase 2Results posted
• Tremelimumab With Chemoembolization or Ablation for Liver CancerCompletedNCT01853618Phase 1/2Results posted
• Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid CancerCompletedNCT01502410Phase 2Results posted
• MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by SurgeryCompletedNCT01425879Phase 2Results posted
• TRC105 for Liver Cancer That Has Not Responded to SorafenibCompletedNCT01375569Phase 2Results posted
• Sorafenib and TRC105 in Hepatocellular CancerCompletedNCT01306058Phase 1/2Results posted
• MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous TherapyTerminatedNCT01239355Phase 2Results posted
• Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary CancersTerminatedNCT01229111Phase 2Results posted
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
• Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by SurgeryTerminatedNCT00835679Early Phase 1Results posted
• IMC-A12 in Treating Patients With Advanced Liver CancerCompletedNCT00639509Phase 2Results posted
• Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver CancerCompletedNCT00604721Phase 2Results posted
• Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by SurgeryTerminatedNCT00459108Phase 2Results posted
• AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver CancerTerminatedNCT00427973Phase 2Results posted
• Bevacizumab and Erlotinib in Treating Patients With Advanced Liver CancerCompletedNCT00365391Phase 2Results posted
• Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By SurgeryCompletedNCT00321594Phase 1/2Results posted
• Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract CancerCompletedNCT00107536Phase 2Results posted
• Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By SurgeryCompletedNCT00101036Phase 2Results posted
• Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or GallbladderTerminatedNCT00085410Phase 2Results posted
• Doxorubicin and Bortezomib in Treating Patients With Liver CancerCompletedNCT00083226Phase 2Results posted
• Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver CancerCompletedNCT00055692Phase 2Results posted
• A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal MalignanciesWithdrawnNCT06690281Phase 2
• A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver CancerActive, not recruitingNCT05211323Phase 2
• National Translational Science Network of Precision-based Immunotherapy for Primary Liver CancerCompletedNCT04145141
• Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract CarcinomaActive, not recruitingNCT03937830Phase 2
• Natural History Study of Children and Adults With Fibrolamellar Hepatocellular CarcinomaWithdrawnNCT03748927
• Gut Microbiota in People With Hepatocellular Carcinoma (HCC)WithdrawnNCT02599909
• Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation TherapyActive, not recruitingNCT02381561Phase 1
• Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By SurgeryWithdrawnNCT01859182Phase 2
• Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung CancerTerminatedNCT01282333Phase 1
• A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver MetastasesCompletedNCT01120288Phase 1
• Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver CancerCompletedNCT01008566Phase 1
• The Natural History of Solid Organ Cancer Stem Cells (SOCSC)TerminatedNCT00923052
• A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore AreaCompletedNCT00913757
• Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By SurgeryCompletedNCT00608361Phase 1
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
• Genetic Susceptibility to Oncogenic VirusesCompletedNCT00341484
• Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver CancerCompletedNCT00238394Phase 2
• EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNCT00087191Not applicable
• Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid TumorsCompletedNCT00081848Phase 1
• Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)CompletedNCT00077441Phase 2
• Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)CompletedNCT00071994Phase 2
• Oxaliplatin in Treating Patients With Liver CancerCompletedNCT00052364Phase 2
• Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver DysfunctionCompletedNCT00047346Phase 1
• Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically RemovedTerminatedNCT00047333Phase 2
• Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder CancerCompletedNCT00033462Phase 2
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Hepatic Arterial Infusion With Melphalan in Treating Patients With Unresectable Liver CancerCompletedNCT00030082Phase 1
• Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic CancerCompletedNCT00028496Phase 1
• BMS-247550 in Treating Patients With Liver or Gallbladder CancerTerminatedNCT00023946Phase 2
• Temozolomide and O6-benzylguanine in Treating Children With Solid TumorsCompletedNCT00020150Phase 1
• Liposomal Doxorubicin in Treating Children With Refractory Solid TumorsCompletedNCT00019630Phase 1
• Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid TumorsCompletedNCT00019331Phase 2
• Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by SurgeryCompletedNCT00006016Phase 2
• Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically RemovedCompletedNCT00006006Phase 2
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Gene Therapy in Treating Patients With Cancer of The LiverTerminatedNCT00003147Phase 1
• A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the LiverCompletedNCT00001587Phase 1
• A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the LiverCompletedNCT00001576Phase 1